Community Corner
Cheshire's Alexion: $1 Billion Annual Revenue
First quarter report better than expected; linked to Soliris sales.
Profits for Cheshire-based Pharmaceuticals Inc. were better than expected, Reuters reports, based on strong sales of Soliris, a genetic disorder drug.
Alexion now expects its adjusted earnings of $1.65 to $1.75 per share, compared with its prior forecast of $1.60 to $1.70 per share, according to Reuters.
Revenue for the year is now forecast to hit $1.084 billion, the company reports. Shares closed at $91.94 on Monday on the Nasdaq.
Find out what's happening in Cheshirewith free, real-time updates from Patch.
Get more local news delivered straight to your inbox. Sign up for free Patch newsletters and alerts.
We’ve removed the ability to reply as we work to make improvements. Learn more here
